All eyes are on Tilray (NASDAQ:TLRYfollowing the release of its second quarter financial results on Tuesday (August 28), since — according to a portfolio manager — the company is a leading candidate to an alcohol producer’s entry into the cannabis space.

Doug Waterson, CFO and Portfolio Manager with Faircourt Asset Management and Manager of the Ninepoint UIT Alternative Health Fund told the Investing News Network (INN) a “highly significant portion” of Tilray’s recent gains were due to speculation of the company serving as a partner for the entry of alcohol producer, Diageo plc (NYSE:DEO).

Rumors began swirling following a report citing the entry of the alcohol producer into the cannabis scene, leading to speculation as to which company was closest to any kind of deal–with fingers pointing to Tilray.

“[Tilray is] a quality name in the space and it would make a good partner for someone looking to enter [like a] beverage company,” Waterson said.

As a result, shares of Tilray increased on Wednesday (August 29) and closed with a 20.64 percent price increase to reach US$62.13. After hours trading brought the company’s share price down 2.54 percent to US$60.55. By Thursday’s (August 30) trading session, the producer’s stock dipped 4.93 percent to reach a closing price of US$58.63.

Waterson added Tilray’s advantage compared to other cannabis names speculated in the race for a deal with Diageo, is its recent relationship to pharmaceuticals and non-exposure into the volatile US cannabis market.

The executive and portfolio manager told INN he thinks investors need to remember this potential deal might not match the famous Constellation Brands (NYSE:STZ) relationship with Canopy Growth (TSX:WEED,NYSE:CGC).

“I think investors should keep in mind that a transaction with a beverage company could take many forms… there are lots of other ways for the companies to work together that might not have that same impact but [can] still be meaningful,” Waterson said. He cautioned investors assuming a rush towards a “controlled position kind of investment.”

Constellation made a second investment into Canopy, adding C$5 billion into the production of the company in international markets. This decision sent cannabis stocks rushing as the markets saw the investment as another sign of maturity for the growing industry.

Waterson said he expects to see the number of deals between cannabis companies and established industries to increase. However, he added those moves won’t be only in Canada, signaling to the global trend of cannabis legalization.

Experts have agreed as the cannabis industry continues growing established markets like pharmaceuticals, tobacco and alcohol would make attempts at entries into the emerging space.

“I would say it’s more important to [the tobacco industry] to do a deal but it’s also probably more difficult,” Waterson said, citing the political and optics issues entry from tobacco would cause as a potential barrier of entry.

In terms of Tilray’s financial results, Brendan Kennedy, president and CEO of the producer, gave credit to global strategy and a multinational distribution network.

Tilray reported C$12.7 million in revenue for the quarter by selling 1,514 kilograms of cannabis and rising its average net selling price from C$8.12 to C$8.36. The producer also reported a net loss of C$12.8 million.

The company has gained value in the Canadian market as it secured supply agreements for legal adult-use cannabis to BC, Manitoba, Nova Scotia, Ontario, Quebec, Yukon and the Northwest Territories.

Investor takeaway

Tilray made its debut in the public markets earlier this year in July when it launched its initial public offering (IPO). The producer opted for the NASDAQ exchange and offered 10.350 million shares of class 2 common stock at a price of US$17 per share.

Since its launch in the public markets, Tilray’s stock has surged rapidly and so far in the year has increased a whopping 177.49 percent.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

 Matica Enterprises Inc. (CSE: MMJ) (OTCQB: MMJFF) (FSE: 39N) (“Matica” or the “Company”) reports the Company has granted 6,500,000 stock options exercisable at $0.05 for five years from date of grant. These include 4,000,000 options to two officers (who are also directors) and, 2,500,000 to two consultants.

For more information on Matica Enterprises please visit the website at:

Keep reading... Show less

The Company welcomes adult-use customers at its eight dispensaries across the state and will create 120 new jobs in surrounding communities

– Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced it will begin serving adult-use consumers across its eight dispensaries in Arizona .

Keep reading... Show less

Harvest Health & Recreation Inc. (“Harvest”) (CSE: HARV, OTCQX: HRVSF), a vertically integrated cannabis company and multi-state operator in the U.S., today announced the launch of recreational cannabis sales in Arizona .

Keep reading... Show less

Jason Mitchell Co-Founder, Director and Chief Executive Officer, HempFusion Wellness Inc. (“HempFusion” or the “Company”) (TSX: CBD.U), and his team joined David Chelich Sector Head, Global Energy and Diversified Industries, TMX Group, to celebrate the Company’s new listing on Toronto Stock Exchange and open the market.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it is one of the seventeen companies in the U.S. and Canada that will be included in the First Psychedelics Exchange Traded Fund, which is managed by Horizons ETF Management.

The Horizons Psychedelic Stock Index ETF index is expected to start trading on Tuesday, January 26, under the ticker PSYK on the NEO exchange.

Keep reading... Show less